Equillium (EQ) Income from Continuing Operations (2018 - 2026)
Equillium's (EQ) quarterly Income from Continuing Operations came in at 15947000.0 in Q1 2026, down 81.36% year-on-year from 85553368.52 in Q1 2025, and down 298.58% on a QoQ basis from 4001000.0 in Q4 2025.
Equillium (EQ) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Income from Continuing Operations data on file, last reported at 15947000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 81.36% year-over-year to 15947000.0 in Q1 2026; TTM through Mar 2026 was 34778000.0, a 145.52% decrease from a year earlier, with the FY2025 full-year figure at 22398000.0, down 176.31% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 15947000.0, down from 4001000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for EQ reached as high as 17908000.0 in Q4 2022 and fell as low as 37417000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 6678058.82 across 5 years, with a median of 4001000.0 in 2025.
- Across the five-year window, Income from Continuing Operations surged 268.26% in 2022 and slumped 124528.57% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 17908000.0 in 2022, then plunged by 119.9% to 3564000.0 in 2023, then sank by 63.66% to 5833000.0 in 2024, then jumped by 31.41% to 4001000.0 in 2025, then slumped by 298.58% to 15947000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 15947000.0 in Q1 2026, 4001000.0 in Q4 2025, and 8724000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Equillium | 258.99 Mn | 258.99 Mn | - | -15.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.95 Mn |
| Dec 31, 2025 | -4.00 Mn |
| Sep 30, 2025 | -8.72 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -8.79 Mn |
| Dec 31, 2024 | -5.83 Mn |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | -3.71 Mn |
| Jun 30, 2023 | -3.34 Mn |
| Mar 31, 2023 | -3.94 Mn |
| Dec 31, 2022 | 17.91 Mn |
| Sep 30, 2022 | -13.66 Mn |
| Jun 30, 2022 | -14.13 Mn |
| Mar 31, 2022 | -37.42 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -18.89 Mn |
| Jun 30, 2021 | -14.73 Mn |